SCHEMBL1721055

SCHEMBL1721055

CCOC(=O)CCC1=CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GLA P06280 1/20 0.42
HPGD P15428 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PDK4 Q16654 1/20 0.42
GRM5 P41594 10/20 0.41
GRM1 Q13255 10/20 0.40
NAMPT P43490 1/20 0.39
ESR2 Q92731 1/20 0.38
NR1H2 P55055 1/20 0.37
HTR6 P50406 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
JAK1 P23458 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5392226 0.88 PDK4 (0.46) ADORA1PDK4GRM5GRM1NAMPT
SCHEMBL1721731 0.83 CYP4F2 (0.40) ALDH1A1L3MBTL1
SCHEMBL597913 0.82 PDK4 (0.45) ADORA1PDK4GRM5GRM1NAMPT
SCHEMBL4532704 0.82 PDK4 (0.46) ADORA1PDK4GRM5GRM1NAMPT
SCHEMBL12566963 0.82 PDK4 (0.48) ADORA1PDK4GRM5GRM1NAMPT
SCHEMBL7677696 0.81 PDK4 (0.44) ADORA1PDK4GRM5GRM1NAMPT
SCHEMBL7987553 0.81 PDK4 (0.46) ADORA1PDK4GRM5GRM1NAMPT
SCHEMBL23852710 0.80 ADORA1 (0.45) ADORA1PDK4GRM5GRM1NAMPT
SCHEMBL2002272 0.79 PDK4 (0.48) ADORA1PDK4GRM5GRM1NAMPT
SCHEMBL12931062 0.78 ADORA1 (0.53) ADORA1ALDH1A1GLAPDK4GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406251-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2012-01-18 EP disclosed
WO-2010103334-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-09-16 WO disclosed